Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Home - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 712603 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Company search
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Viewing report

Order by Fax
Printer Friendly
Send to Friend
Enquire before Buying
Hard Copy  Add to Basket
Electronic (PDF)  Add to Basket
Enterprisewide  Add to Basket



Cubist Pharmaceuticals Inc: Strategic Corporate Assessment - Strategy, SWOT Analysis and 5-year Financial Insights with In-depth Company Profile
Datamonitor, Aug 2008, Pages: 53


  Description  
  Table of Contents  
    
    
    
   
 Enquire before Buying  
 Send to a Friend  

Cubist Pharmaceuticals is a biopharmaceutical company focused on the research, development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. Cubicin, Cubists major product, is approved for multiple indications in many countries. In the US, Cubicin is being marketed for the treatment of complicated skin structure infections (cSSI).

Scope

- Contains corporate strategy, value chain presence and SWOT Analysis

- Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors

- Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights of this title

Cubist has one marketed product, Cubicin, an antibiotic from a class of antiinfectives called lipopeptides, for the treatment of complicated skin and skin structure infections, and for other blood-stream infections. The companys research and development programs include lipopeptide programs.

Cubist has research collaboration with Ilypsa to develop ILY103, a non-antibiotic, toxin binder therapy for the treatment of clostridium difficile associated diarrhea which is in preclinical trials.

Cubist derives its revenues from the product sales of Cubicin and other revenues which includes license agreements revenues, Small Business Innovation Research (SBIR) and grant revenue. Cubists total revenues increased at a CAGR of 103% during 2002-2006, from $11 million in 2002 to $195 million in 2006.

Key reasons to purchase this title

- Access all the important information and analysis on the company in a single report

- Understand companys strengths, weaknesses, opportunities and threats along with business strategy and value chain

- Gain access to companys adjusted five year financial data along with key ratios and market capitalization




Customers who bought this item also bought

Growth Strategies In Premium And Indulgent Food And Drinks To 2008: Increasing Profitability And Market Share

Cubist Pharmaceuticals Inc: Strategic Corporate Assessment - Strategy, SWOT Analysis and 5-year Financial Insights with In-depth Company Profile

Global Market Review of Premium Beer ? Forecasts to 2013

The Growth of Premium Marketing

Developing Products With A Price Premium

Premium Company Profile: Depomed

Premium Company Profile Cytogen

Premium Company Profile Dyax



Top of page


   All rights reserved. ? Copyright 2010 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster


Research and Markets RSS Feeds